Results 121 to 130 of about 44,547 (282)

Early Weight Regain After GLP‐1 Receptor Agonist Discontinuation: Mechanisms and Implications for Treatment De‐Escalation Strategies

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have transformed the pharmacological management of obesity, producing substantial and sustained weight loss during active treatment. However, discontinuation of therapy is frequently followed by significant weight regain, raising important questions regarding the durability of treatment ...
M. A. Damhof, F. H. van Bruggen, E. N. van Roon   +2 more
wiley   +1 more source

Perceived Stress, Hair Cortisol and Hair Cortisone in Relation to Appetite-Regulating Hormones in Patients with Obesity

Obesity Facts
Introduction: Stress predicts unhealthy eating, obesity, and metabolic deterioration, likely mediated by altered levels of appetite- and metabolism-regulating hormones.
Susanne Kuckuck, Robin Lengton, Renate E.H. Meeusen, Eline S. van der Valk, Manon H.J. Hillegers, Brenda W.J.H. Penninx, Maryam Kavousi, Jenny A. Visser, Mariëtte R. Boon, Sjoerd A.A. van den Berg, Elisabeth F.C. van Rossum   +10 more
doaj   +1 more source

The Role of Oxidative Stress in Periodontitis

Journal of Periodontal Research, EarlyView.
Oxidative stress is involved in multiple chemical reactions that take place in different intracellular organelles: mitochondria, rough endoplasmic reticulum, peroxisomes, autophagy, and aging, and can be influenced by exogenous factors: nutrition, physical activity, psychological status, environmental conditions, microbiome, and drugs.
Pedro Bullon, Francesca Giampieri, Beatriz Bullon, Maurizio Battino   +3 more
wiley   +1 more source

Effects of gastric inhibitory polypeptide on leucine- and arginine-stimulated insulin release

, 1983
Insulin release stimulated by single amino acids, with and without gastric inhibitory polypeptide (GIP), was studied in vivo in anesthetized rats and in vitro in collagenase-digested isolated rat pancreatic islets.
L. Ciofalo, L. A. Waters, L. DePalma, J. C. Groshong, E. L. Mazzaferri, G. H. Starich   +5 more
core   +1 more source

Effects of Glucagon‐Like Peptide‐1 Receptor Agonists (Mono and Combination Therapy) on Energy Expenditure: A Scoping Review

Obesity Reviews, EarlyView.
ABSTRACT Introduction Weight loss results in reduced energy expenditure (EE) due to body composition alterations (e.g., fat‐free mass and fat mass losses) and mass‐independent adaptations in EE (e.g., hormones). Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) are indicated for obesity management; however, their effects on EE remain unclear ...
Flavio T. Vieira, ZhiDi Deng, Manfred J. Muller, Giovanna G. L. Bergamasco, Sarah Cawsey, Melania Manco, Steven B. Heymsfield, Carla M. Prado, Andrea M. Haqq   +8 more
wiley   +1 more source

Food-dependent Cushing's syndrome mediated by aberrant adrenal sensitivity to gastric inhibitory polypeptide.

, 1992
peer reviewedBACKGROUND: Some patients with Cushing's syndrome have nodular adrenal hyperplasia. In most the disease is corticotropin-dependent, but in others it is corticotropin-independent. The cause of the adrenal hyperplasia in the latter patients is
Leroyer, R., Georges Travert, Travert, G., LEBRETHON, Marie-Christine, Ilse Budi, Anne-Marie Balliere, Pierre Leymarie, Marie-Christine Lebrethon, Mahoudeau, J., Allali-Zerah, V., Robert Leroyer, Balliere, A. M., Leymarie, P., Budi, I., Jacques Mahoudeau, Jean A. Chayvialle, Reznik, Y., Veronique Allali-Zerah, Chayvialle, J. A., Yves Reznik   +19 more
core   +1 more source

Low Weight Loss Response to Incretin Analogs: A Systematic Review

Obesity Reviews, EarlyView.
ABSTRACT The development of GLP‐1 and GIP analogs has been a significant breakthrough in type 2 diabetes and obesity pharmacotherapy. However, individual responses to these medications can vary widely. This systematic review examines factors associated with low or no weight loss response to GLP‐1 and GIP analogs. Key predictors of poor response include
Pamela S. Gaskin, Peter S. Chami
wiley   +1 more source

Innovations in Obesity Treatment: Beyond Adipose Tissue Dysfunction

Obesity Reviews, EarlyView.
Obesity drives chronic inflammation, insulin resistance, type 2 diabetes, and cancer development through adipocyte dysfunction. Addressing this multisystemic disorder requires integrated strategies beyond diet and exercise, such as thermogenesis activation via menthol or capsinoids and appetite control through GLP‐1/GIP agonists and neuromodulation to ...
Jesica Martínez‐Godfrey, Irene Pomares‐Bri, Paula de Juan‐Maciá, Mariló Olivares‐Vicente, Enrique Barrajón‐Catalán, Vicente Micol, Enrique Roche, María Herranz‐López   +7 more
wiley   +1 more source

Interaction of arginine and gastric inhibitory polypeptide on insulin release in man

, 1982
The interrelations of the insulin secretagogues, glucose, arginine (Arg), and gastric inhibitory polypeptide (GIP) were quantified in six normal young men in five sets of experiments with the hyperglycemic clamp technique (125 mg/dl above basal glucose ...
R. J. Hershcopf, D. C. Muller, D. K. Andersen, G. S. Raizes, J. D. Tobin, R. Andres, D. Elahi   +6 more
core   +1 more source

Effects of GLP-1 and GIP on cholinergic-induced contractility in isolated jejunal muscle from obese patients with and without type 2 diabetes mellitus

Frontiers in Physiology
BackgroundIntestinal dysmotility in type 2 diabetes mellitus (T2DM) may involve impaired cholinergic and incretin-mediated regulation. This study compared cholinergic-induced jejunal contractility and evaluated the effects of Glucagon like peptide-1 (GLP-
Mantas Malinauskas, Darius Stukas, Kristina Rysevaite-Kyguoliene, Rita Gudaityte, Limas Kupčinskas, Anna Casselbrant, Lina Jankauskaite, Almantas Maleckas   +7 more
doaj   +1 more source